Baidu
map

ASCO 2014:多发肺毛玻璃结节的NSCLC不一致的驱动基因突变的发生率

2014-05-31 Alex 译 医学论坛网

摘要号:#11068 第一作者:任胜祥,上海市肺科医院肿瘤科 标题:多发肺毛玻璃结节的NSCLC不一致的驱动基因突变的发生率 背景:在各种恶性肿瘤包括非小细胞肺癌中都已经发现了Intertumor异质性。与肺外转移相比,多肺结节患者具有显著较高的异质性。本研究的目标是在有多个肺内毛玻璃结节(GGNs)的非小细胞肺癌(NSCLC)患者中,比较已知的驱动突变的分布

摘要号:#11068

第一作者:任胜祥,上海市肺科医院肿瘤科

标题:多发肺毛玻璃结节的NSCLC不一致的驱动基因突变的发生率

背景:在各种恶性肿瘤包括非小细胞肺癌中都已经发现了Intertumor异质性。与肺外转移相比,多肺结节患者具有显著较高的异质性。本研究的目标是在有多个肺内毛玻璃结节(GGNs)的非小细胞肺癌(NSCLC)患者中,比较已知的驱动突变的分布。

方法:在一个研究所(同济大学,上海,中国),35名双肺多发GGNs的连续切除的肺癌患者接受了基因突变分析,包括EGFR , KRAS , HER2 , BRAF和PIK3CA,同时也分析了融合基因ALK , ROS1和RET。

结果:中位年龄为60岁,男/女: 12/23 ,从未吸烟者/吸烟者:25/ 10 ,PS 0 / 1 : 22/13 。共72个病灶被纳入这个分析,包括9个原位腺癌,9微创腺癌和54浸润性腺癌。其中,33(45.8%)个肿瘤有EGFR基因突变,其中13个在19号外显子缺失,18个L858R错义突变,2个同时具有19号外显子缺失和L858R错义突变,5(6.9%)个有EML4-ALK基因融合,4(5.6%)个有HER2基因突变,3(4.2%)个有KRAS突变,1个同时有ROS1基因融合和BRAF基因突变。大多数的突变是相互排斥的,除了1个既有EGFR突变和ALK基因融合。驱动突变分布的不一致频率是68.6%(24/35),而在患者中检测到至少有一个驱动突变的概率是80%(24/30)。在2例切除了3个肺部病灶的患者中,有一例患者的3个肿瘤样本中,分别发现了外显子21 L858R点突变,外显子19缺失,以及L858R点突变同时又有ALK融合。

结论:在这项研究的多个肺内肿瘤结节中,驱动突变分布的高发不一致性表明,这些GGNs也许发生的是独立事件,这就导致了肺内结节较高的异质性。具有多GGNs的患者应该给予一个单独的分期和治疗策略。

研究链接:Incidence of inconsistent driver mutations between multiple lung ground-glass nodules in patients with non-small cell lung cancer.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2026456, encodeId=575820264567f, content=<a href='/topic/show?id=53ff10150942' target=_blank style='color:#2F92EE;'>#驱动基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101509, encryptionId=53ff10150942, topicName=驱动基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sat Aug 09 20:41:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826257, encodeId=ff5a182625e77, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Nov 02 11:41:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938352, encodeId=16d4193835279, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Mar 16 07:41:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661474, encodeId=1fed16614e479, content=<a href='/topic/show?id=34a110150800' target=_blank style='color:#2F92EE;'>#驱动基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101508, encryptionId=34a110150800, topicName=驱动基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b94625296381, createdName=751943081_32627957, createdTime=Fri Apr 24 20:41:00 CST 2015, time=2015-04-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2026456, encodeId=575820264567f, content=<a href='/topic/show?id=53ff10150942' target=_blank style='color:#2F92EE;'>#驱动基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101509, encryptionId=53ff10150942, topicName=驱动基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sat Aug 09 20:41:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826257, encodeId=ff5a182625e77, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Nov 02 11:41:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938352, encodeId=16d4193835279, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Mar 16 07:41:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661474, encodeId=1fed16614e479, content=<a href='/topic/show?id=34a110150800' target=_blank style='color:#2F92EE;'>#驱动基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101508, encryptionId=34a110150800, topicName=驱动基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b94625296381, createdName=751943081_32627957, createdTime=Fri Apr 24 20:41:00 CST 2015, time=2015-04-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2026456, encodeId=575820264567f, content=<a href='/topic/show?id=53ff10150942' target=_blank style='color:#2F92EE;'>#驱动基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101509, encryptionId=53ff10150942, topicName=驱动基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sat Aug 09 20:41:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826257, encodeId=ff5a182625e77, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Nov 02 11:41:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938352, encodeId=16d4193835279, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Mar 16 07:41:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661474, encodeId=1fed16614e479, content=<a href='/topic/show?id=34a110150800' target=_blank style='color:#2F92EE;'>#驱动基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101508, encryptionId=34a110150800, topicName=驱动基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b94625296381, createdName=751943081_32627957, createdTime=Fri Apr 24 20:41:00 CST 2015, time=2015-04-24, status=1, ipAttribution=)]
    2015-03-16 quxin068
  4. [GetPortalCommentsPageByObjectIdResponse(id=2026456, encodeId=575820264567f, content=<a href='/topic/show?id=53ff10150942' target=_blank style='color:#2F92EE;'>#驱动基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101509, encryptionId=53ff10150942, topicName=驱动基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sat Aug 09 20:41:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826257, encodeId=ff5a182625e77, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Nov 02 11:41:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938352, encodeId=16d4193835279, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Mar 16 07:41:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661474, encodeId=1fed16614e479, content=<a href='/topic/show?id=34a110150800' target=_blank style='color:#2F92EE;'>#驱动基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101508, encryptionId=34a110150800, topicName=驱动基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b94625296381, createdName=751943081_32627957, createdTime=Fri Apr 24 20:41:00 CST 2015, time=2015-04-24, status=1, ipAttribution=)]

相关资讯

ASCO 2014:类美坦素偶联物靶向治疗结肠癌的临床前评价

摘要号:#3048 作者:Feng Liang,德克萨斯理工大学生命科学中心药学;姚航平,浙江大学医学部 标题:抗酪氨酸激酶受体RON的抗体药物——类美坦素偶联物 (anti-RON ADC)靶向治疗结肠癌的临床前评价 背景:受体酪氨酸激酶RON是影响肿瘤发生的关键,经证实也是靶向药物治疗的关键靶点。本文中我们报道了抗RON抗体的mAbZt/g4-maytan

ASCO 2014:索凡替尼的研磨制剂治疗晚期实体瘤的Ⅰ期临床试验

摘要号:2615 第一作者:徐建明,军事医学科学院附属307医院 标题:选择性VEGFR/FGFR双重抑制剂索凡替尼治疗晚期实体瘤患者的Ⅰ期临床试验 背景:索凡替尼是以血管细胞内皮生长因子受体 (VEGFR) 和成纤维细胞生长因子受体 (FGFR) 为靶点的口服选择性小分子酪氨酸激酶抑制剂。原成份的Ⅰ期临床试验研究数据已在2013的ASCO会议上有所报道。而其

ASCO 2014:18F-FETNIM PET/CT可无创性评估脑胶质瘤的缺氧程度

摘要号:11100 第一作者:胡曼,山东省肿瘤医院放疗科 标题:18F-氟赤式硝基咪唑 (18F-FETNIM) PET/CT测定的缺氧程度与脑胶质瘤恶性进展的相关性研究 背景:缺氧是人脑胶质瘤的重要生物学特征。PET提供了一种无创性的方法来区分个体肿瘤生物学,并相应的修改治疗方案。PET示踪剂的发展为评估人类肿瘤的缺氧提供了更好的工具。本研究的目的是通过使用

ASCO 2014:NSCLC患者血清循环DNA的EGFR突变检测

摘要号:#11094 第一作者:Zongfei Li,北京协和医院检验科 标题:血清循环DNA的EGFR突变检测 背景:作为EGFR靶向药物之一,EGFR酪氨酸激酶抑制剂(TKI)在NSCLC患者的治疗中发挥着重要作用。EGFR的突变是肿瘤对EGFR-TKI敏感的可靠标记物。本文中,我们评估了血清中循环DNA(ctDNA)中EGFR突变与肿瘤的一致性,并且评估

ASCO 2014:化疗+恩度可显著提高骨肉瘤患者生存期

摘要号:# 10538 第一作者:徐海荣,北京积水潭医院骨肿瘤外科 标题:一项受控的,非随机的IIB期骨肉瘤化疗联合再结合内皮抑素的临床研究 背景:本研究目的在于探讨化疗联合再结合内皮抑素(恩度)对于IIB期骨肉瘤的疗效及安全性。 方法:来自北京积水潭医院2008年1月至2012年4月诊断为IIB期骨肉瘤的患者分为联合治疗组和对照组。其化疗方

ASCO 2014:hhpg-19K可预防晚期NSCLC患者化疗的骨髓抑制

摘要号:#9614 第一作者:周彩存,上海同济大学附属肺科医院 标题:聚乙二醇重组人粒细胞刺激因子(hhpg-19K)预防晚期非小细胞肺癌患者化疗骨髓抑制的Ⅲ期研究——一项多中心随机双盲对照Ⅲ期研究 背景:HHPG-19K(19K)是一种长效的聚乙二醇化重组粒细胞集落刺激因子,在每个化疗周期给药一次。该III期研究的目的是调查HHPG-19K作为预防性治疗接受

Baidu
map
Baidu
map
Baidu
map